Uncategorized
ThromboGenics announces positive long-term study results of Jetrea in VMA patients
ThromboGenics announced positive topline results from the OASIS study of Jetrea in patients with symptomatic vitreomacular adhesion, according to a press release.The randomized, sham-controlled, double-masked study collected data to determine the long-term safety and efficacy of Jetrea (ocriplasmin) injection in a 24-month follow-up period for the treatment of vitreomacular adhesion (VMA). It is the company’s first controlled study of the product since results of its phase 3 program were announced in 2011, the release said.